Nick Morrell
@NickMorrell15
Followers
1K
Following
8K
Media
29
Statuses
846
Clinician scientist, lung doc, co-Founder of Morphogen-IX and Interact Bio Ltd, developing better treatments for pulmonary arterial hypertension.
Cambridge, UK
Joined June 2018
ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport https://t.co/x9XTK4wjrQ Great to see this out. Wonderful collaboration with @PeterVangheluwe and team!
academic.oup.com
AbstractAims. Potential loss-of-function variants of ATP13A3, the gene encoding a P5B-type transport ATPase of undefined function, were recently identified
0
3
13
We have had lots of fun this morning celebrating the announcement of a £16 million gift to HLRI and are thrilled to change our name in honour of our generous benefactor. We are grateful to Victor & our other wonderful partners incl @TheBHF @papworthcharity @cftrust @wolfsonfdn
We are delighted to announce that today we have become the Victor Phillip Dahdaleh Heart & Lung Research Institute to honour a very generous philanthropic donation from @victordahdaleh
@Cambridge_Uni @RoyalPapworth @CUHPartners
6
8
82
We are delighted to announce that today we have become the Victor Phillip Dahdaleh Heart & Lung Research Institute to honour a very generous philanthropic donation from @victordahdaleh
@Cambridge_Uni @RoyalPapworth @CUHPartners
1
17
44
Join Centessa and the Rare Disease community to help raise awareness of #RareDisease. Show your stripes in honor of #RareDiseaseDay and visit @RareDisease's website to get involved: https://t.co/ti5wpBzfcW
0
2
6
A lifetime pleasure to give a plenary talk at my home conference #winterBTS2022
Inspiring talk from @mark_toshner showing a genuine bench to bedside approach to help transform the research approach in a rare disease - including remote/digital monitoring to help patient involvement. Brilliant. #BTSWinter2022
3
3
50
Centessa hosted @PHAssociation & individuals living with PH for an event to raise awareness of this complex disease. Learn how you can help spread awareness #PulmonaryArterialHypertension.
0
3
5
Proud moment! My First, First Author paper is finally published! Happy Monday News! 🥳 An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis ➡️ https://t.co/pR79PmF1NB
@CommsBio #PAH #PhD #PhDChat Here's the Tweetorial👇
nature.com
Communications Biology - A biomimetic inducible model of pulmonary arterial hypertension (PAH) is presented, combining natural and induced BMPR2 dysfunction with hypoxia in lung endothelial cells...
19
26
186
Amazing Accomplishment: our first joint paper is published in Blue Journal @ATSBlueEditor !! Huge Thanks to all contributors and especially to Justyna Karolak for the leadership! Big research value, but also huge increase of credibility for TBX4Life! #tbx4
https://t.co/MALlvTQrYy
1
5
14
Today we announced that new data from an additional 18-months of continued treatment with SerpinPC from the OLE of our Phase 2a Study of SerpinPC in hemophilia was accepted for oral presentation at the 64th ASH Annual Meeting on Sat., Dec. 10 at 2:15pm CT. https://t.co/mpEfSv5Pcu
0
5
7
It's #PulmonaryHypertension Awareness Month. Centessa's advancing MGX292 as part of our mission to develop transformational medicines for patients with #PulmonaryArterialHypertension. Visit @PHAssociation to learn more about PH Awareness month: https://t.co/Y5RDVU8sif
0
3
4
Great job of the International Consortium for Genetic Studies in PAH. Proud to be part of this dynamic team. @Pulmotension @Respifil @InsermU999 Genetic counselling and testing in pulmonary arterial hypertension - A consensus statement https://t.co/KutPDu97eH
0
17
21
Fantastic to see @RxCelerate Founder and CEO, Jill Reckless, featured in Sunday Times! https://t.co/qSfrC7ZxPR Jill has been an inspiration to just about everyone she has ever worked with
2
3
23
Today we announced a poster presentation of data from our oral small-molecule orexin receptor 2 (OX2R) agonist discovery pipeline at #SleepEurope 2022. The poster will be presented in Athens on Thurs., Sept. 29 at 12:15pm EEST. Read our press release:
investors.centessa.com
– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd – BOSTON and...
0
9
39
Thrilled to announce that US Orphan Drug designation was granted to SerpinPC, our novel inhibitor of activated protein C, being investigated as a treatment of #hemophiliaB. We look forward to initiating registrational studies for SerpinPC later this year. https://t.co/4lPT1YjhTJ
0
5
10
LockBody is hiring! Looking for talented, passionate scientists who want to change the future of cancer therapy:
1
1
10
Today is a historic day for @TheBHF, as we announce #CureHeart as the winner of our £30m #BigBeatChallenge 🔬 I'm unbelievably proud that this incredible research, funded by our amazing supporters, could lead to the first cures for people with inherited muscle heart diseases
4
23
112
The peppered moth - never actually seen one in real life before (although this one sadly dead). One of the first evolutionary stories we heard at school featured this beautiful creature.
1
0
11
Our TBX4 paper has just been accepted for publication in @ATSBlueEditor !! Happy of having shared this scientific journey with so many giants in the field! Official twit when we have it online 🥳🥳🥳🥳
First genotype-phenotype study in TBX4 syndrome: gain-of-function mutations causative for lung disease https://t.co/zwfRVv37Zo
#medRxiv
2
2
18
Honoured to host HRH Duchess of Gloucester at our official opening of the Cambridge Heart and Lung Research Institute yesterday. Now the real work begins to undertake high impact translational science to benefit patients with cardiopulmonary conditions! @BHF @RoyalPapworth
5
16
123